Bank of America Corp DE Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Bank of America Corp DE boosted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 1,178.9% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,710,303 shares of the company’s stock after buying an additional 1,576,568 shares during the period. Bank of America Corp DE owned approximately 0.83% of Taysha Gene Therapies worth $2,959,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new position in Taysha Gene Therapies in the fourth quarter valued at approximately $41,000. Ameriprise Financial Inc. acquired a new stake in Taysha Gene Therapies in the fourth quarter valued at approximately $40,000. Jane Street Group LLC grew its position in Taysha Gene Therapies by 57.6% in the fourth quarter. Jane Street Group LLC now owns 169,575 shares of the company’s stock valued at $293,000 after acquiring an additional 62,003 shares in the last quarter. Northern Trust Corp grew its position in Taysha Gene Therapies by 6.3% in the fourth quarter. Northern Trust Corp now owns 1,458,732 shares of the company’s stock valued at $2,524,000 after acquiring an additional 86,207 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Taysha Gene Therapies in the fourth quarter valued at approximately $135,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ:TSHA opened at $2.71 on Friday. The business’s fifty day moving average price is $1.92 and its two-hundred day moving average price is $1.90. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $4.32. The stock has a market capitalization of $581.73 million, a price-to-earnings ratio of 4.30 and a beta of 0.90. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. As a group, analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on TSHA shares. JMP Securities raised their price target on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a “market outperform” rating in a research report on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Monday, April 28th. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Finally, Chardan Capital lifted their price objective on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $7.00.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.